The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Indacaterol / glycopyrronium / mometasone inhaler (Enerzair Breezhaler®) has been accepted for use as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Indacaterol / mometasone inhaler (Atectura Breezhaler®) has been accepted for use as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.
Glycopyrronium / formoterol inhaler (Bevespi Aerosphere®) has been rejected for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. The manufacturer failed to make a submission for this indication.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - April 2021||Drug Safety Update - May 2021 »|